Addressing Dementia Via Agitation-Centered Evaluation
Trial details
- Registry ID
- NCT03226522
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Addressing Dementia Via Agitation-Centered EvaluationNCT03226522 | AXSM | Phase 2, Phase 3 | Completed | 2020-04-17Actual |
| Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)NCT07766655 | AXSM | Phase 3 | Recruiting | 2027-12Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |